Sentence examples similar to rationale of evaluation from inspiring English sources

These studies provided the rationale for evaluation of bortezomib as a modifier of cell-cell adhesion and cellular packing density in solid tumours.

Although polymorphisms were not directly evaluated by Innocenti and colleagues, their clinical report suggested flavopiridol∶metabolite ratio as a possible predictor of diarrhea with flavopiridol treatment and provided a rationale for evaluation of a genetic link with UGT isoforms [31].

Our results thus provide a rationale for evaluation of combination therapy with ALK and MEK inhibitors in EML4 ALK-positive NSCLC patiEML4 ALK-positive iNSCLCtors alone show little effect.

The potent antitumour properties demonstrated in this model of spontaneous bronchoalveolar carcinoma provide a strong rationale for additional evaluation of CCL19 regulation of tumour immunity and its use in immunotherapy for lung cancer.

This latter analysis is the focus of this article in which we aim to understand the rationale behind the choice of evaluation approaches and to highlight and critique solutions proposed in the evaluation reports we examined.

Our results also provide a rationale for clinical evaluation of the combinations of bortezomib and oridonin (or other inhibitors of NF-κB1/2) or AD 198 (or other drugs targeting c-Myc) in the treatment of lymphoma and MM, especially in patients containing TRAF3 deletions or relevant mutations.

Relative dose escalation, increased biological effectiveness and oxygen independence of radiation effect therefore provide a rationale for the evaluation of particle therapy in the multi-modality treatment of advanced SCCHN.

In summary, our results support an increased anti-tumour effect of combined inhibition of Wee1 and Chk1/2 and provide a rationale for further evaluation of the kinases as therapeutic targets in human melanomas.

These data provide a rationale for further evaluation of the combination of Wee1 and Chk1/2 inhibitors in malignant melanoma.

The above observations would create a rationale for future evaluation of cabozantinib in earlier stages of prostate cancer, such as in the adjuvant setting for high-risk disease or hormone-sensitive disease.

Inhibition of excessive receptor activation in the lung and in the heart in PAH provides a strong rationale for clinical evaluation of such agents in the treatment of PAH and RVF.